Biogen Initiates Phase 1 Trial for New SKYCLARYS Tablet Formulation to Improve Patient Access in Friedreich's Ataxia
核心洞察
Biogen has launched a Phase 1 bioequivalence study comparing a new tablet-for-oral-suspension formulation of SKYCLARYS (omaveloxolone) against the current capsule form in healthy adults.
The new liquid-ready formulation aims to help patients with Friedreich's ataxia (搜索) who have difficulty swallowing capsules, potentially improving treatment adherence and convenience.
The randomized, open-label crossover study will evaluate whether both formulations deliver equivalent drug absorption and processing in the body while monitoring safety signals.
Biogen Inc. has initiated a Phase 1 clinical trial to evaluate a new tablet-for-oral-suspension formulation of SKYCLARYS (omaveloxolone), the company's approved treatment for Friedreich's ataxia (搜索). The bioequivalence study aims to determine whether the new liquid-ready form delivers the same therapeutic benefits as the current capsule formulation while addressing patient accessibility challenges.
Study Design and Objectives
The Phase 1 trial, officially titled "A Phase 1, Randomized, Open-Label, Single-Dose, Crossover, Bioequivalence Study of Omaveloxolone Tablets for Oral Suspension Versus Capsules in Healthy Adult Participants," is designed as a two-period crossover study in healthy volunteers. All participants will receive both formulations in different sequences with a washout period between doses.
The primary objective focuses on bioequivalence assessment, comparing how much drug enters the bloodstream and the rate of absorption between the tablet-for-suspension and capsule forms. The study will also monitor basic safety and tolerability signals for both formulations.
Addressing Patient Needs
The new tablet-for-oral-suspension formulation specifically targets patients who experience difficulty swallowing capsules, a common challenge in neurological conditions like Friedreich's ataxia (搜索). By dissolving the tablet in liquid, the formulation could improve treatment convenience and adherence for affected patients.
The study tests omaveloxolone (BIIB141), which is already approved for Friedreich's ataxia (搜索) treatment. Participants receive the same active pharmaceutical ingredient through both delivery methods, ensuring therapeutic consistency while potentially expanding treatment accessibility.
Trial Timeline and Status
The study began recruiting participants in December 2025, with the most recent update to the ClinicalTrials.gov record occurring on January 7, 2026. The trial protocol includes a screening period of up to 28 days, followed by approximately 30 days in the research unit, with total participant involvement spanning up to 57 days.
Key data readouts will follow the primary completion date when all participants complete dosing and main measurements. Final study completion will occur after comprehensive data analysis and verification processes are finished.
Strategic Implications
The bioequivalence study represents Biogen's life-cycle management approach to enhancing its rare disease portfolio value without requiring new efficacy demonstrations. Successful bioequivalence would enable the company to offer a more flexible SKYCLARYS formulation without conducting large-scale efficacy trials.
This strategy could strengthen Biogen's competitive position in Friedreich's ataxia (搜索) treatment while supporting steady revenue generation in the rare disease market. The approach also helps protect pricing strategies, reduce patient switching risks, and maintain physician confidence in the treatment option.
The development occurs as Biogen faces emerging competition from genetic and RNA-based therapies in rare neurological diseases. Bioequivalent formulations can help maintain market position by addressing practical patient needs while preserving therapeutic efficacy.
The ongoing study is registered under NCT07297199 on ClinicalTrials.gov, where complete trial details and updates are available for healthcare professionals and researchers monitoring Friedreich's ataxia (搜索) treatment developments.